Navigating Blue Shield of California Xarelto Prior Authorization

Efficiently manage Blue Shield of California Xarelto prior authorization requests with a clear understanding of payer-specific requirements and submission channels.

For revenue cycle directors and prior authorization coordinators, navigating the complexities of anticoagulant approvals is critical. This guide provides an executive overview of the Blue Shield of California (BSCA) prior authorization process for Xarelto (rivaroxaban), a direct oral anticoagulant (DOAC) commonly prescribed for indications such as atrial fibrillation and venous thromboembolism (VTE).

Xarelto (Rivaroxaban) Coverage with Blue Shield of California

Xarelto, or rivaroxaban, is a direct oral anticoagulant (DOAC) indicated for conditions including atrial fibrillation and the treatment or prevention of VTE. As with many specialty pharmaceuticals, Blue Shield of California's coverage for Xarelto typically requires prior authorization. Formulary tier placement and step therapy requirements for rivaroxaban can vary by specific BSCA plan, necessitating a review of the member's benefit plan and current formulary.

Blue Shield of California Prior Authorization Submission Channels for Xarelto

**Medical Benefit PA:** For Xarelto administered under the medical benefit (e.g., inpatient or provider-administered), submissions route through the Blue Shield Provider Connection portal at blueshieldca.com or via X12 278 transactions through clearinghouses. The Availity portal may also serve as an access point.
**Pharmacy Benefit PA:** For Xarelto dispensed under the pharmacy benefit, prior authorization workflows are managed by Blue Shield of California's contracted PBM. The specific PBM partner requires verification, as national Blue Cross Blue Shield plans utilize various administrators.
**Specialty Drug PA:** As a specialty drug, Xarelto PA follows either the medical or pharmacy benefit channels depending on how it is billed. Medical-benefit specialty drugs follow standard medical PA processes; pharmacy-benefit specialty drugs follow the configured specialty pharmacy operations.

Accessing Utilization Management Policies for Rivaroxaban

Blue Shield of California publishes its medical policy and clinical utilization management (UM) guideline libraries on its provider website. For rivaroxaban, specific policy numbers and effective dates should be referenced. BSCA medical policies disclose whether criteria are internally developed, based on MCG guidelines, or sourced from other clinical compendia.

California Regulatory Impact on Xarelto Prior Authorization Turnaround Times

California's regulatory environment significantly impacts PA turnaround times. HMO plans are regulated by the California Department of Managed Health Care (DMHC), while PPO plans fall under the California Department of Insurance (CDI), each with distinct PA requirements. Additionally, BSCA Medicare Advantage, Medi-Cal managed care, and Covered California plans are subject to phased PA timeframes mandated by federal CMS-0057-F.

Common Denial Reasons and Appeal Pathways for Anticoagulants

Denials for anticoagulant prior authorizations, including Xarelto, often stem from issues such as lack of documentation for medical necessity, non-compliance with step therapy protocols, or incomplete submission data. Blue Shield of California communicates denial reasons via standard X12 277/835 transactions and portal status updates. The appeal pathway is documented in BSCA's provider manual. External review options include the DMHC's Independent Medical Review (IMR) program for HMO plans, a separate external review process for CDI-regulated PPO plans, the CMS 5-level appeal structure for Medicare Advantage, and DHCS-mandated grievance procedures for Medi-Cal.

Frequently asked questions

How do I submit a Xarelto prior authorization to Blue Shield of California?

Medical benefit Xarelto PAs are submitted via the Blue Shield Provider Connection portal or X12 278. Pharmacy benefit PAs are handled by BSCA's PBM partner; confirm the specific PBM and their submission portal for rivaroxaban.

What are the typical turnaround times for Xarelto PA with Blue Shield of California?

Turnaround times are governed by California state regulations (DMHC for HMOs, CDI for PPOs) and federal CMS-0057-F mandates for Medicare Advantage, Medi-Cal, and Covered California plans. Always check the specific plan type for applicable timeframes.

Does Blue Shield of California require step therapy for Xarelto?

Formulary requirements, including step therapy for Xarelto (rivaroxaban), can vary significantly by Blue Shield of California plan. It is essential to verify the member's specific benefit plan and the current formulary for applicable rules.

Where can I find Blue Shield of California's medical policies for rivaroxaban?

Blue Shield of California publishes its medical policy and clinical utilization management guidelines, including those for rivaroxaban, on its provider website. Always reference the specific policy number and effective date.

What is the appeal process for a denied Xarelto prior authorization with BSCA?

The initial appeal process is outlined in the BSCA provider manual. If denied internally, external review options include the DMHC IMR program (HMO), CDI external review (PPO), CMS 5-level appeals (Medicare Advantage), or DHCS grievance procedures (Medi-Cal).